OSCR enters the week after earnings with an uncomfortable split: the stock fell 7.3% on its August 6 print, then bounced 5.1% Friday — but the more durable tension sits in the insider register, where CEO Mark Bertolini sold roughly $70 million of stock in the final days of June.
The insider selling is the defining story here. Bertolini offloaded more than 1.83 million shares across four trading days between June 25 and June 30, at prices ranging from $28.60 to $29.79, for total proceeds close to $48 million in those sessions alone. Founder Mario Schlosser added another ~$1.5 million in sales on July 1. In aggregate, the insider register shows net selling of roughly $104 million over the past 90 days — at a stock now trading at $27.90, below the prices at which those sales were made. That the CEO was reducing a position worth tens of millions of dollars just before an earnings day that moved the stock down 7.3% is a data point the market cannot easily dismiss.
The short-interest picture adds context but not alarm. Bears have been building gradually: SI % of free float has climbed from roughly 7.3% in late June to 8.6% today, a 17% rise over the month. Yet borrow remains cheap at 0.52% annualised — elevated 60% over the prior month but still in "easy" territory — and share availability is essentially unconstrained at over 9,700% of outstanding short interest. That means the borrow market is wide open; shorts face no meaningful squeeze pressure. Options are similarly relaxed, with the put/call ratio at 0.44, hugging its 20-day average and well off the 52-week high of 0.74. Neither the lending market nor the options surface is signalling elevated fear.
The Street is more constructive than the tape. Barclays analyst Andrew Mok — who upgraded OSCR to Overweight back in June — raised his price target on Friday to $39 from $35, a 39% premium to Friday's close. That move changes the story at the margin: it's a same-day post-earnings upgrade from a firm that has been consistently more bullish on the name and now sits well above the consensus mean target of $28.20. The bull case rests on 29% revenue growth in Q2, an 91.1% medical loss ratio that came in below expectations, and a growth trajectory in premiums per member that analysts project accelerating through 2026 and 2027. The bear case is structural: ACA Marketplace enrollment could fall 20-30% if enhanced subsidies expire, putting roughly six million members at risk and compressing the revenue base just as Oscar is scaling. EPS momentum factor scores rank in the 91st and 97th percentile over 30 and 90 days respectively — the earnings track record has been strong — but those scores were assembled before a print that sent the stock down 7%.
The ownership table adds one more layer worth noting. Vanguard entered the register in Q1 2026 with a full new position of 10.5 million shares. Mark Bertolini himself holds 6.15 million shares after his June sales — his position shrank by 4.2 million shares in the quarter. The co-CEO Mario Schlosser holds 2.4 million shares and trimmed 520,000 in the same period. That two founders and C-suite sellers were active at prices above $28 while the stock now trades below those levels is a data point the register will carry into the next quarter.
The next scheduled earnings date is September 16. Between now and then, the key variable is any policy development on ACA subsidy extension — the enrollment trajectory that determines whether the bull case on premium growth per member holds, or whether the bear case on member attrition starts to materialise in the data.
See the live data behind this article on ORTEX.
Open OSCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
